Page 34 - 3DA Mag N° February2018 -EN+

MEDICINE

A rare or orphan disease is any disease
that affects a very small percentage of the
population. In Europe a disease is consi-
dered to be rare when it affects fewer than
1 in 2000 people; in the US as fewer than
200,000 American at any given time. It is
so rare that there is a lack of a market large
enough to gain support and resources for
discovering treatments for it.
However, this issue of rare diseases arouses
the interest of some pharmaceutical
companies such as Cycle Pharmaceuticals
which has made it its core business.
Founded 6 years ago by James Harrison
(now Executive Chairman of the Board of
INTERVIEW Directors), it is run by Antonio Benedetti,
CEO.
Accompanied by Steve Fuller, Business
Development Director of Cycle, Antonio
Benedetti talked about the difficulties faced
How can 3D printed by patients who suffer from rare diseases
today, but above all, one of the solutions

orphan drugs improve that the company proposes to reduce these
obstacles and improve the quality of life of
patients.
life of patients? This solution which results from a partnership
with Aprecia Pharmaceuticals, a company
The point of view of specialized in the 3D Printing (3DP) of drugs,
explores the possibilities offered to patients
Antonio Benedetti, with rare diseases. Possibilities that can
drastically improve their quality of life and
CEO of Cycle raise the interest of the healthcare industry.
Aprecia, expects to use its ZipDose®
Pharmaceuticals Technology to transform the way people
take medicine. ZipDose® Technology can
be combined with a wide variety of active
pharmaceutical ingredients to create rapidly
disintegrating oral dosage forms that are
easy to take and easy to administer.

Magazine / February 2018